Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MELK | Q14680 | 3/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | KAT7 | O95251 | 1/20 | 0.33 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19963011 | 0.99 | DRD2 (0.39) | DRD2MELKGPR119KAT7KAT5 | |
| SCHEMBL19962964 | 0.97 | DRD2 (0.37) | DRD2MELKGPR119CREBBPRIPK2 | |
| SCHEMBL19962966 | 0.95 | MELK (0.35) | DRD2MELKGPR119RIPK2GABRA2 | |
| SCHEMBL19962907 | 0.91 | PIK3CA (0.35) | DRD2MELKGPR119KAT5RIPK2 | |
| SCHEMBL21130682 | 0.91 | AXL (0.33) | DRD2MELKGPR119RIPK2AXL | |
| SCHEMBL19962961 | 0.90 | GPR119 (0.32) | DRD2MELKGPR119RIPK2AXL | |
| SCHEMBL19962965 | 0.90 | GPR119 (0.32) | DRD2MELKGPR119RIPK2AXL | |
| SCHEMBL21130653 | 0.90 | RIPK2 (0.37) | MELKGPR119CREBBPRIPK2 | |
| SCHEMBL21130652 | 0.89 | MELK (0.33) | MELKGPR119RIPK2 | |
| SCHEMBL21130681 | 0.88 | GPR119 (0.33) | DRD2MELKGPR119RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | FGH BIOTECH, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018049080-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | FGH BIOTECH, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339142-B2 | Di-substituted pyrazole compounds for the treatment of diseases | SREBF1, SREBF2, CYP27A1 | DRD2 4559/4885MELK 1854/4885GPR119 38/4885 |
| US-20190194167-A1 | DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES | SREBF1, SREBF2, CYP27A1 | DRD2 4559/4885MELK 1854/4885GPR119 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.